OTCQB Podcast

Flux Power Holdings, Inc. (OTCQB: FLUX) develops and markets advanced lithium-ion energy storage systems. Ron Dutt, CEO of Flux, joins us to discuss the company's proprietary battery management system, along with its in-house engineering and product design.

Vahan Ajamian, Managing Director of Analyst Relations for Medmen Enterprises Inc. (OTCQB: MMNFF) joins our podcast to discuss the company's approach to cannabis in Canada and the United States.

Focused on uranium exploration in Namibia, Deep Yellow Ltd. (OTCQB: DYLLF) is a development company listed on the Australian Stock Exchange. John Borshoff joins the podcast to provide an overview of the company and explain why the company chose to cross trade on the OTCQB Venture Market.

SinglePoint, Inc. (OTCQB: SING) focuses on acquiring companies that will benefit from the injection of growth capital and technology integration. Gregory Lambrecht, CEO of SinglePoint chats with us about the company's acquisition philosophy.

Zach Bair, CEO of VNUE, Inc. (OTCQB: VNUE) joins our podcast to explain how the company and its products support artists and provide transparency to the music industry.

Gary Macleod, CEO and James Whelan, CTO of AlphaPoint Technology Inc. (OTCQB: APPO), a technology holding and software application development company, stopped by our offices in New York during Consensus 2018 to discuss the company's initiatives.

Cornerstone Metals (OTCQB: CCCCF) is a Vancouver based mineral exploration company that's focused on advancing the Carlin Vanadium Project in North Central Nevada. Paul Cowley, President & CEO of Cornerstone joins our podcast to provide an update on the project and the company.

James Thompson CEO of Callitas Health Inc. (OTCQB: MPHMF), an integrated clinical-stage pharmaceutical development and OTC consumer goods marketing company, joins our OTCQB podcast to update listeners on the company's product development.

Bravada Gold Corporation (OTCQB: BGAVF) is a Nevada-focused exploration and development company, exploring for precious metals in well-established gold trends in one of the world's best gold jurisdictions. CEO, Joseph A. Kizis, Jr. joins our podcast to discuss the company's initiatives.

Humanigen, Inc. (OTCQB: HGEN) is a biopharmaceutical company pursuing cutting-edge science to develop our proprietary monoclonal antibodies for immunotherapy and oncology treatments. Joining our podcast today is Cameron Durrant, Chairman and CEO.